✦ LIBER ✦

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years

✍ Scribed by Christopher J. E. Watson; J. Andrew Bradley; Peter J. Friend; John Firth; Craig J. Taylor; John R. Bradley; Kenneth G. C. Smith; Sathia Thiru; Neville V. Jamieson; Geoff Hale; Herman Waldmann; Roy Calne

Book ID: 114803432
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 101 KB
Volume: 5
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2005.00822.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of Alemtuzumab (Campath-1H) as Induc

Use of Alemtuzumab (Campath-1H) as Induction Therapy in Pediatric Kidney Transplantation

✍ E.T. Ona; R.A. Danguilan; J. Africa; C.B. Cabanayan-Casasola; Z.L. Antonio; M.A. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Campath-1H (Alemtuzumab) as an Induction

Campath-1H (Alemtuzumab) as an Induction Agent for the Prevention of Graft Rejection and Preservation of Renal Function in Kidney Transplant Patients: Philippine 3-Year Follow-up

✍ A.S. Muñoz; C.B. Cabanayan-Casasola; R.A. Danguilan; F.B. Padua; E.T. Ona 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Randomized Phase 2b Trial of Tofacitinib

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

✍ F. Vincenti; H. Tedesco Silva; S. Busque; P. O’Connell; J. Friedewald; D. Cibrik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

A Prospective, Randomized, Multicenter S

A Prospective, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Two Dosing Regimens of Daclizumab Compared to No Antibody Induction in Simultaneous Kidney–Pancreas Transplantation: Results at 3 Years

✍ R.J. Stratta; R.R. Alloway; A. Lo; E.E. Hodge 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 71 KB